Tff pharmaceuticals and cleveland clinic to advance multivalent universal influenza vaccine candidates into preclinical testing

Fort worth, texas, may 20, 2024 (globe newswire) -- tff pharmaceuticals, inc (nasdaq: tffp) (the “company” or “tff pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented thin film freezing (tff) technology platform, today announced that, in collaboration with cleveland clinic, the company is advancing multiple multivalent universal influenza vaccines to protect against seasonal and pandemic viruses into preclinical testing. the decision to advance the vaccine candidates into preclinical testing was based upon the successful completion of formulation testing with stability data on the combination of hemagglutinin (ha) antigens with four different adjuvants. based on these data, three ha antigen/adjuvant candidate vaccines have been selected for testing in a pre-clinical model at cleveland clinic florida.
UVV Ratings Summary
UVV Quant Ranking